Sameer S Kadri1,2, Bruce J Swihart3, Stephanie L Bonne4, Samuel F Hohmann5,6, Laura V Hennessy7, Peter Louras7, Heather L Evans7, Chanu Rhee8, Anthony F Suffredini1, David C Hooper2, Dean A Follmann3, Eileen M Bulger7, Robert L Danner1. 1. Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland. 2. Division of Infectious Diseases, Massachusetts General Hospital, Boston. 3. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. 4. Department of General Surgery, Barnes Jewish Hospital, St Louis, Missouri. 5. Vizient, and. 6. Department of Health Systems Management, Rush University, Chicago, Illinois. 7. Department of Surgery, Harborview Medical Center, Seattle, Washington; and. 8. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Abstract
BACKGROUND: Shock frequently complicates necrotizing fasciitis (NF) caused by group A Streptococcus (GAS) or Staphylococcus aureus. Intravenous immunoglobulin (IVIG) is sometimes administered for presumptive toxic shock syndrome (TSS), but its frequency of use and efficacy are unclear. METHODS: Adult patients with NF and vasopressor-dependent shock undergoing surgical debridement from 2010 to 2014 were identified at 130 US hospitals. IVIG cases were propensity-matched and risk-adjusted. The primary outcome was in-hospital mortality and the secondary outcome was median length of stay (LOS). RESULTS: Of 4127 cases of debrided NF with shock at 121 centers, only 164 patients (4%) at 61 centers received IVIG. IVIG subjects were younger with lower comorbidity indices, but higher illness severity. Clindamycin and vasopressor intensity were higher among IVIG cases, as was coding for TSS and GAS. In-hospital mortality did not differ between matched IVIG and non-IVIG groups (crude mortality, 27.3% vs 23.6%; adjusted odds ratio, 1.00 [95% confidence interval, .55-1.83]; P = .99). Early IVIG (≤2 days) did not alter this effect (P = .99). Among patients coded for TSS, GAS, and/or S. aureus, IVIG use was still unusual (59/868 [6.8%]) and lacked benefit (P = .63). Median LOS was similar between IVIG and non-IVIG groups (26 [13-49] vs 26 [11-43]; P = .84). Positive predictive values for identifying true NF and debridement among IVIG cases using our algorithms were 97% and 89%, respectively, based on records review at 4 hospitals. CONCLUSIONS: Adjunctive IVIG was administered infrequently in NF with shock and had no apparent impact on mortality or hospital LOS beyond that achieved with debridement and antibiotics. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Shock frequently complicates necrotizing fasciitis (NF) caused by group A Streptococcus (GAS) or Staphylococcus aureus. Intravenous immunoglobulin (IVIG) is sometimes administered for presumptive toxic shock syndrome (TSS), but its frequency of use and efficacy are unclear. METHODS: Adult patients with NF and vasopressor-dependent shock undergoing surgical debridement from 2010 to 2014 were identified at 130 US hospitals. IVIG cases were propensity-matched and risk-adjusted. The primary outcome was in-hospital mortality and the secondary outcome was median length of stay (LOS). RESULTS: Of 4127 cases of debrided NF with shock at 121 centers, only 164 patients (4%) at 61 centers received IVIG. IVIG subjects were younger with lower comorbidity indices, but higher illness severity. Clindamycin and vasopressor intensity were higher among IVIG cases, as was coding for TSS and GAS. In-hospital mortality did not differ between matched IVIG and non-IVIG groups (crude mortality, 27.3% vs 23.6%; adjusted odds ratio, 1.00 [95% confidence interval, .55-1.83]; P = .99). Early IVIG (≤2 days) did not alter this effect (P = .99). Among patients coded for TSS, GAS, and/or S. aureus, IVIG use was still unusual (59/868 [6.8%]) and lacked benefit (P = .63). Median LOS was similar between IVIG and non-IVIG groups (26 [13-49] vs 26 [11-43]; P = .84). Positive predictive values for identifying true NF and debridement among IVIG cases using our algorithms were 97% and 89%, respectively, based on records review at 4 hospitals. CONCLUSIONS: Adjunctive IVIG was administered infrequently in NF with shock and had no apparent impact on mortality or hospital LOS beyond that achieved with debridement and antibiotics. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low Journal: Clin Infect Dis Date: 1999-04 Impact factor: 9.079
Authors: M S Bergdoll; B A Crass; R F Reiser; R N Robbins; A C Lee; P J Chesney; J P Davis; J M Vergeront; P J Wand Journal: Ann Intern Med Date: 1982-06 Impact factor: 25.391
Authors: A Norrby-Teglund; R Kaul; D E Low; A McGeer; D W Newton; J Andersson; U Andersson; M Kotb Journal: J Immunol Date: 1996-04-15 Impact factor: 5.422
Authors: Martin B Madsen; Peter B Hjortrup; Marco B Hansen; Theis Lange; Anna Norrby-Teglund; Ole Hyldegaard; Anders Perner Journal: Intensive Care Med Date: 2017-04-18 Impact factor: 17.440
Authors: Scott L Weiss; Mark J Peters; Waleed Alhazzani; Michael S D Agus; Heidi R Flori; David P Inwald; Simon Nadel; Luregn J Schlapbach; Robert C Tasker; Andrew C Argent; Joe Brierley; Joseph Carcillo; Enitan D Carrol; Christopher L Carroll; Ira M Cheifetz; Karen Choong; Jeffry J Cies; Andrea T Cruz; Daniele De Luca; Akash Deep; Saul N Faust; Claudio Flauzino De Oliveira; Mark W Hall; Paul Ishimine; Etienne Javouhey; Koen F M Joosten; Poonam Joshi; Oliver Karam; Martin C J Kneyber; Joris Lemson; Graeme MacLaren; Nilesh M Mehta; Morten Hylander Møller; Christopher J L Newth; Trung C Nguyen; Akira Nishisaki; Mark E Nunnally; Margaret M Parker; Raina M Paul; Adrienne G Randolph; Suchitra Ranjit; Lewis H Romer; Halden F Scott; Lyvonne N Tume; Judy T Verger; Eric A Williams; Joshua Wolf; Hector R Wong; Jerry J Zimmerman; Niranjan Kissoon; Pierre Tissieres Journal: Intensive Care Med Date: 2020-02 Impact factor: 17.440
Authors: A Albasanz-Puig; D Rodríguez-Pardo; C Pigrau; M Lung; E Roldan; P S Corona; B Almirante; I Ruiz-Camps Journal: Ann Hematol Date: 2020-05-12 Impact factor: 3.673
Authors: Ahmed Babiker; Xiaobai Li; Yi Ling Lai; Jeffrey R Strich; Sarah Warner; Sadia Sarzynski; John P Dekker; Robert L Danner; Sameer S Kadri Journal: Lancet Infect Dis Date: 2020-12-14 Impact factor: 25.071